MYCN and neuroblastoma: To validate MYCN binding to the promoter of SNRPD3 we performed Chromatin Immunoprecipitation (ChIP) with anti-MYCN and IgG antibodies followed by quantitative real time PCR (RT-qPCR) using primers that target the CAGGTG E-box ( + 647 bp upstream of the SNRPD3 transcription start site (TSS)) and a negative control (Control; −2000 bp downstream of SNRPD3 TSS) region in the MYCN-amplified human neuroblastoma SK-N-BE(2)-C and KELLY cell lines (Fig. 2B).